NCT05474352 is a EARLY_PHASE1 clinical trial of Allon System in Hyperthermic Intraperitoneal, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05474352?

NCT05474352 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05474352?

Interventions in NCT05474352: Allon System.

What condition does NCT05474352 study?

NCT05474352 studies Hyperthermic Intraperitoneal.

Is NCT05474352 still recruiting?

NCT05474352 is currently withdrawn. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT05474352

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Water Warming/Cooling Garment to Maintain a Constant Intraoperative Core Target Temperature in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Proof-of-Concept Study

Withdrawn EARLY_PHASE1 Last updated 6 May 2023

What this trial tests

EARLY_PHASE1 trial testing Allon System in Hyperthermic Intraperitoneal. Withdrawn.

Timeline

14 June 2022

Primary endpoint
3 May 2023

3 May 2023

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	EARLY_PHASE1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Start date	14 June 2022
Primary completion	3 May 2023
Estimated completion	3 May 2023
Sites	1 location across United States

Drugs / interventions tested

Allon System

Conditions studied

Hyperthermic Intraperitoneal — all drugs for Hyperthermic Intraperitoneal →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Hyperthermic Intraperitoneal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To look at the feasibility of using a water warming/cooling garment (called the ALLON system) to maintain a target body temperature during surgery and chemotherapy perfusion (a method of pouring chemotherapy throughout your abdominal cavity) without overheating or overcooling your body.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05474352 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05474352.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing